Medical inquiries

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

SPRAVATO® (esketamine)

Medical Information

+ Save link

SPRAVATO - Residual Medication in Used Devices

Last Updated: 01/17/2025

SUMMARY

To mitigate the risks of abuse and misuse of SPRAVATO, the nasal spray device for SPRAVATO is manufactured as a disposable, single-use, single-dose product that is difficult to disassemble and produces a minimal residual amount of drug after it is used.

The average residual volume after use is approximately 30 μL.¹
It is not possible to administer another dose from a device after 2 sprays have been delivered.²

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 17 December 2024.

References

Show

1	The U.S. Food and Drug Administration (FDA). Janssen briefing information for the February 12, 2019, joint meeting of the PDAC and the DSaRM. 2019- [cited 2024 December 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211243Orig1s000RiskR.pdf
2	Data on File. Esketamine. Email Communication.